The Cleveland Clinic and its partner, Anixa Biosciences, recently received approval from the U.S. Food and Drug Administration to start a Phase I trial “for what could be the first-ever vaccine to prevent triple-negative breast cancer.”
“Our translational research program focuses on developing vaccines that prevent diseases we confront as we age, like breast, ovarian and endometrial cancers.
“If successful, these vaccines have the potential to transform the way we control adult-onset cancers and enhance life expectancy in a manner similar to the impact that the childhood vaccination program has had,” said Dr. Vince Tuohy, Ph.D., the primary inventor of the vaccine and immunologist at the Lerner Research Institute of the Cleveland Clinic, in a statement.
“Aside from this trial, the researchers are anticipating another study on the same vaccine, involving participants who are healthy and without breast cancer but at risk for developing the disease and have undergone a voluntary mastectomy to reduce their risks.
“These participants usually carry gene mutations in either BRCA1 or BRCA2, which predisposes them to triple-negative breast cancer or any other type of breast cancer.”
Read more here.